Top

BMC Neurology

Published in:

Open Access 01-12-2020 | Multiple Sclerosis | Research article

Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran

Authors: Ali Imani, Farid Gharibi, Ali Khezri, Nasrin Joudyian, Koustuv Dalal

Published in: BMC Neurology | Issue 1/2020

Abstract

Background

Multiple sclerosis (MS) causes significant economic burden to the patients, families, health systems and society. This study aimed to estimate the annual economic costs incurred by patients with multiple sclerosis (pwms) at different levels of the disease.

Method

This was a cross-sectional study, using the Expanded Disability Status Scale (EDSS) tool for assessing the disease level of 300 (=N) pwms in East Azerbaijan province, Iran. To estimate the cost of MS, a questionnaire with its validity and reliability (CVR 92% and CVI 87%) and pilot test (Cronbach’s alpha score 0.89) was used. The data were collected by interviewing pwms and reviewing their clinical records. Multivariate linear regression was used to assess the relationship between disease levels and incurred costs.

Results

The results revealed that the mean annual cost for pwms in Iran is 97,521,740 IRR (equivalent to 2321.94 USD; 1978.93 EURO) and the mean score of EDSS in pwms was 3.14. The annual cost incurred by pwms with mild, moderate and severe levels of disease were 83,918,150 IRR (1998.05 USD; 1702.88EURO), 137,772,660 IRR (3280.30 USD; 2795.71 EURO) and 119,962,670 IRR (2856.25 USD;2434.30 EURO), respectively. Also, on average, each increase in EDSS score in pwms in Iran led to increase 8,139,260 IRR (equivalent to 193.79 USD; and 165.16 EURO) in total annual cost which must paid from pwms and their households exclusively. Also, there was a significant relationship between total annual cost and disease severity in such a way that any increase in EDSS degree is led to 8,139,260 IRR (193.79 USD; 165.16 EURO) added cost for pwms.

Conclusion

The study results could be helpful for Iranian health managers to solve problems which are facing by the patients with multiple sclerosis and their families.

GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–85.CrossRef

Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4(9):556–66.PubMedCrossRef

Svendsen B, Myhr KM, Nyland H, Aarseth JH. The cost of multiple sclerosis in Norway. Eur J Health Econ. 2012;13(1):81–91.PubMedCrossRef

Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol. 2002;249(2):152–63.PubMedCrossRef

Casado V, Romero L, Gubieras L, Alonso L, Mora E. Martı’nez-Ye’lamos S, et al. an approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler J. 2007;13(6):800–4.CrossRef

Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Rev Pharmacoecon Outcomes Res. 2006;6(2):145–54.PubMedCrossRef

Kobelt G, Lindgren P, Smala A, Joˆnsson B. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ. 2001;2:60–8.CrossRef

Hibbard PL. The use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann NEUROol. 1994;36(2):S218–130.CrossRef

Kobelt G, Berg J, Lindgren P, Jonsson B. Costs and quality of life in multiple sclerosis in EUROope: method of assessment and analysis. Eur J Health Econ. 2006;7(2):S5–S13.PubMedCrossRef

10.

Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11(7):e0159129.PubMedPubMedCentralCrossRef

11.

Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ. 2006;7(2):S86–95.PubMedCrossRef

12.

Strober LB, Christodoulou C, Benedict R, Westervelt HJ, Melville P, Scherl WS, et al. Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler J. 2012;18(5):647–53.CrossRef

13.

Pompeii LA, Moon SD, McCrory DC. Measures of physical and cognitive function and work status among individuals with multiple sclerosis: a review of the literature. J Occup Rehabil. 2005;15(1):69–84.PubMedCrossRef

14.

Ghandehari K, Riasi HR, Nourian A, Boroumand AR. Prevalence of multiple sclerosis in north east of Iran. Mult Scler. 2010;16:1525–6.PubMedCrossRef

15.

Maghzi AH, Ghazavi H, Ahsan M, Etemadifar M, Mousavi SA, Khorvash F. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Mult Scler. 2010;16:359–61.PubMedCrossRef

16.

Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol. 2007;79:357–75.PubMedCrossRef

17.

Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan. Iran Mult Scler. 2011;17:1022–7.PubMedCrossRef

18.

Bezzini D, Battaglia MA. Multiple sclerosis epidemiology in EUROope. Adv Exp Med Biol. 2017;958:141–59.PubMedCrossRef

19.

Cheong WL, Mohan D, Warren N, Reidpath DD. Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected NEUROological Disease. Front Neurol. 2018;9:432.PubMedPubMedCentralCrossRef

20.

Hartung DM, Bourdette DN, Ahmed SM. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84(21):2185–92.PubMedPubMedCentralCrossRef

21.

Mateen FJ. Multiple sclerosis in resource-limited settings: research opportunities in an unequal world. Neurology. 2019;93(4):176–80.PubMedCrossRef

22.

Krejcie V, Morgan DW. Determining sample size for research activities. Educ Psychol Meas. 1970;30:670–10.CrossRef

23.

Kurtzke J. Rating nEUROological impairement in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.PubMedCrossRef

24.

Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ. 2006;7:S75–85.PubMedCrossRef

25.

Gharibi F, Tabrizi JS, Eteraf Oskouiee MA, AsghariJafarabadi M. Effective interventions on service quality improvement in a physiotherapy clinic. Health Promot Perspect. 2014;4(1):61–7.PubMedPubMedCentral

26.

Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ. 2006;7(2):S24–33.PubMedCrossRef

27.

Drummond FM, O’Brien B, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care Programmes. New York: Oxford Medical Publications; 2003.

28.

Dunn J. Impact of mobility impairment on the burden of care giving in individuals with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):433–40.PubMedCrossRef

29.

Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91–8.PubMedCrossRef

30.

Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics. 2009;27(8):681–91.PubMedCrossRef

31.

O’Connor RJ, Cano SJ, Ramio I, Torrenta L, Thompson AJ, Playford ED. Factors influencing work retention for people with multiple sclerosis. Cross-sectional studies using qualitative and quantitative methods. J Neurol. 2005;252(8):892–6.PubMedCrossRef

32.

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in EUROope. Mult Scler. 2017;23(8):1123–36.PubMedPubMedCentralCrossRef

33.

Ponzio M, Gerzeli S, Brichetto G, Bezzini D, Mancardi GL, Zaratin P, et al. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci. 2015;36(2):227–34.PubMedCrossRef

34.

Ziemssen T, Prosser C, Haas JS, Lee A, Braun S, Landsman-Blumberg P, et al. Healthcare resource use and cost of multiple sclerosis patients in Germany before and during fampridine treatment. BMC Neurol. 2017;17(1):62.PubMedPubMedCentralCrossRef

35.

Imani A, Golestani M, Omrani A, Alikhani M, Delpasand M, Vafaee R, et al. Analysis of thraputic expenditure in patients with multiple sclerosis in Iran. Sci J Ilam Univ Med Sci. 2013;21(7):17–177.

36.

Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis a systematic review of the literature. Pharmacoeconomics. 2010;28(5):363–79.PubMedCrossRef

Title: Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran
Authors: Ali Imani
Farid Gharibi
Ali Khezri
Nasrin Joudyian
Koustuv Dalal
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Multiple Sclerosis
Published in: BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-020-01790-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran

Abstract

Background

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Docosahexaenoic acid in ARSACS: observations in two patients

Medium- and long-term effects of endovascular treatments for severely stenotic basilar arteries supported by multimodal imaging

Polymyoclonus aggravated by neck flexion as the isolated presenting symptom of Hirayama disease: case report

HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya

Decreased frontal white-matter diffusion and improved cognitive flexibility after burr-hole surgery in moyamoya angiopathy

Risk factor analysis for progressive spinal deformity after resection of intracanal tumors─ a retrospective study of 272 cases